Business
Napo Pharmaceuticals Expands Mytesi (Crofelemer) Patient Support Program
NapoCares™ patient support program provides FDA-approved, plant-based non-opioid Mytesi® to treat non-infectious diarrhea in adults with HIV/AIDS on
About this update from Jaguar Health, Inc.
[{"type":"text","content":"NapoCares™ patient support program provides FDA-approved, plant-based non-opioid Mytesi® to treat non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapyLaunch of expanded NapoCares program during COVID-19 pandemic should especially benefit Mytesi patients who may have lost jobs or health insuranceNapo, a subsidiary of Jaguar Health, is committed to discovering and developing novel, safe, effective, and responsibly harvested plant-based prescription medicines to meet urgent global health needsSAN FRANCISCO, CA / ACCESSWIRE / April 2, 2020 / Napo Pharmaceuticals, Inc., a wholly owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\"), today announced it will expand NapoCares™, its patient support program for Mytesi® (crofelemer), the Company's FDA-approved plant-based, non-opioid prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adult patients living with HIV (PLWH) on antiretroviral therapy.The expansion raises income limits on patients eligible for the uninsured, free-drug program and significantly increases co-pay support for commercially insured patients, allowing the co-pay amount to remain the same whether a patient fills a 30-day or 90-day prescription of Mytesi. These changes are effective April 1, 2020.\"We want to do what we can to help all Mytesi patients - and the fact that our expanded patient support program is launching during the COVID-19 pandemic should especially benefit Mytesi patients who may have lost jobs or health insurance during the crisis. It is of paramount importance to help keep Mytesi patients safe during this unprecedented public health crisis and help patients remain on treatment to prevent debilitating HIV-related diarrhea,\" Lisa Conte, Jaguar's president and chief executive officer, stated.Under the terms of the expanded access program, the income limit for the Patient Assistance Program (PAP), which offers free drug for uninsured patients, has increased from two-times the Federal Poverty Limit to five-times the Federal Poverty Limit - a 150% increase - and the Mytesi copay benefit for commercially insured patients has increased from an annual maximum of $1,200 to $6,000, a 400% increase. Additionally, co-pay patients can now refill Mytesi prescriptions earlier than every 30 days, fast-start prescriptions will soon...